Irbepress Plus (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbepress Plus, is an angiotensin II receptor blocker (ARB) / thiazide diuretic combination presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients. By reducing vascular resistance and promoting fluid excretion, the combination helps achieve target blood pressure levels.

GNH USA supplies Irbepress Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, sourcing the product from EU‑regulated manufacturers and adhering to stringent quality and regulatory standards.

Irbepress Plus, a combined angiotensin II receptor blocker and thiazide diuretic, is used to treat hypertension and related conditions.

- Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Hypertension in type 2 diabetes: provides blood pressure control and supports renal protection. - Hypertension with mild to moderate renal impairment: aids in achieving desired pressure control while managing fluid balance.

Irbepress Plus may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue or weakness. - Increased urination. - Electrolyte disturbances such as low potassium. - Mild rise in blood glucose levels.

Serious or Rare Side Effects: - Severe allergic reaction (rash, swelling, difficulty breathing). - Acute kidney injury or significant rise in serum creatinine. - Marked hypotension, especially after the first dose. - Pancreatitis. - Severe electrolyte imbalance (hyperkalemia or hyponatremia).

Before initiating therapy, clinicians should consider several safety aspects.

- Renal function: monitor serum creatinine and potassium regularly. - Pregnancy: contraindicated (Category D) due to risk of fetal toxicity. - Elderly patients: start at the lowest effective dose and titrate cautiously. - Concomitant lithium therapy: increased risk of lithium toxicity; monitor serum levels. - Hyperkalemia risk: avoid use with potassium‑sparing diuretics or supplements. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbepress Plus can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia. - Other renin‑angiotensin system blockers (ACE inhibitors, other ARBs): increase risk of renal impairment and hyperkalemia. - Lithium: can raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive efficacy and affect renal function. - CYP2C9 inhibitors (e.g., fluconazole, amiodarone): can elevate irbesartan levels. - Additional antihypertensives (beta‑blockers, calcium channel blockers): may produce additive blood pressure lowering effects.